Symbols

OCGN

Ocugen·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About OCGN

Ocugen, Inc.

A clinical-stage biopharmaceutical company that developing therapies to treat the eye diseases

Industry

Pharmaceutical

Established Date

06/28/2000

Listing Date

12/03/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.ocugen.com

Security Type

Common stock

Office address

11 Great Valley Parkway, Malvern, Pennsylvania 19355

Business

Introduction

Ocugen, Inc., was incorporated on June 28, 2000 under the federal laws of Massachusetts and conducts its principal business operations in Waltham, Massachusetts. The company is a biotechnology company focused on discovering, developing and commercializing novel gene and cell therapies and vaccines that can improve health and bring hope to patients around the world.

Earnings Call

Q1/2025

Estimate EPS-0.06

Actual EPS-0.05

Estimate Revenue--

Actual Revenue1.48M

Contradictions in OCU410ST and OCU200: Insights from the Latest Earnings Call

May 20,2025 02:13·
Earnings Decrypt

Q2/2025

Estimate EPS-0.06

Actual EPS-0.05

Estimate Revenue350.00K

Actual Revenue1.37M

Ocugen's Q2 2025 Earnings Call: Unpacking Contradictions in Trial Timelines, Manufacturing, and Strategic Direction

Aug 01,2025 12:37·
Earnings Decrypt

Company Financials

EPS

OCGN has released its 2025 Q3 earnings. EPS was reported at -0.07, versus the expected -0.06, missing expectations. The chart below visualizes how OCGN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

OCGN has released its 2025 Q3 earnings report, with revenue of 1.75M, reflecting a YoY change of 54.23%, and net profit of -20.05M, showing a YoY change of -54.60%. The Sankey diagram below clearly presents OCGN's revenue sources and cost distribution.